Formas farmacêuticas de libertação modificada

Revista Portuguesa de Farmacia

Volumn 49, Issue 4, 1999, Pages 181-190

  Costa, Paulo ^b   Lobo, J M Sousa ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b NONE

Author keywords

Activation; Diffusion; Dissolution; Erosion; Modified release; Polymeric systems; Release; Solid systems; Transdermal systems

Indexed keywords

EID: 0013310982     PISSN: 0484811X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Amidon, G.L., Lennernas, H., Shah, V.P. e Crison, J.R., Pharm. Res., 12, 413-420 (1995)
2. Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 1997, BP1
3. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on a Biopharmaceutics Classification System, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 1999
4. International Conference on Harmanization, Quality of prolonged release oral solid dosage forms, Guidelines Eudra/Q/91/025, 89-93 (1991)
5. Preamble/Preface, United States Pharmacopoeia XXII/National Formulary XVII, U.S. Pharmacopeial Convention, Rockville, xliii-xliv (1990)
6. Guidance, Oral Extended (Controlled) Release Dosage Forms, In Vivo Bioequivalence And In Vitro Dissolution Testing, Food and Drug Administration, Division of Bioequivalence in the Office of Generic Drugs, informal communication 21, CFR 10.90
7. Arnold, R.J.G. e Kaniecki, D.J., Pharmacy Times, 3: 24-34 (1993)
8. Crank, J., The Mathematics of Diffusion, 2nd Ed., Oxford University Press, 2-10 (1975)
9. Peppas, N.A. e Gurny, R., Pharm. Acta Helv., 58, 2-8 (1983)
10. Peppas, N.A. e Lusting, S.R., Annals New York Academy of Sciences; Volume 446, 26-41 (1985)
11. Santus, G. e Baker,R.W., J. Controlled Release, 35, 1-21 (1995)
12. Prista, L.N., Alves, C.A. e Morgado, R,M., Tecnologia Farmacêutica, Volume III, 4a Edição, Fundação Calouste Gulbenkian, Lisboa, 2060-2064 (1995)
13. Harland, R.H., Gazzaniga, A., Sangalli, M. E., Colombo, P, e Peppas, N.A., Pharm. Res., 5, 488-494 (1988)
14. Colombo, P, Bettini, R., Massimo, G., Catellani, P.L., Santi P. e Peppas, N.A., J. Pharm. Sci., 84, 991-997 (1995)
15. Katzhendler, I., Hofman, A., Goldberger, A. e Friedman, M., J. Pharm. Sci., 86, 110-115 (1997)
16. Narasimhan, B., e Peppas, N.A., J. Pharm. Sci., 86, 297-304 (1997)
17. Kim. H. e Fassihi, R., J. Pharm. Sci., 86, 316-322 (1997)
18. Kim. H. E Fassihi, R., J. Pharm. Sci., 86, 323-328 (1997)
19. Conte, U. e Maggi, L., Pharm. Tech. Europe, 10, 18-25 (1998)
20. Fassihi, R.A. e Ritschel, W.A., J. Pharm. Sci., 82, 750-754 (1993)
21. Sangalli, M.E., Giunchedi, P., Maggi, L., Conte, U. e Gazzaniga, A., Eur. J. Pharm. Biopharm., 40, 370-373 (1994)
22. Santini, J.T. Jr, Cima. M.J., Langer, R., Nature, 28, 335-338 (1999)
23. Costa, P., Provas de aptidão pedagógica e capacidade científica, Faculdade de Farmácia do Porto (1994)
24. Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section I (Pharmacokinetic and Clinical Evaluation), Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, PMP/EWP/280/96 draft
25. Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Quality), Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, CPMP/QWP/604/96 draft